Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Royalty Pharma logo

Royalty Pharma Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Royalty Pharma holds $19.8B in total assets. Shareholders' equity is $9.9B against $9.0B in total debt. Cash and equivalents total $586.4M. The current ratio is 2.66 and debt-to-equity is 0.903. Based on the Q1 2026 filing.

Total Assets$19.8BTotal Stockholders Equity$9.9BLong Term Debt$8.6BCash And Equivalents$586.4MTotal Current Assets$1.4BTotal Current Liabilities$535.7M
Latest FilingQ1 2026
Report Date2026-05-06
Market Cap$24.5B
P/E Ratio29.63
ROE8.39%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$13.4M$37.6M$20.2M$41.4M$19.4M$25.5M
Accrued interest$98.1M$19.2M$85.6M$29M$110.8M$25.3M
Accounts payable and other current liabilities (Note 11)$13.4M$37.6M$20.2M$41.4M$19.4M$25.5M
Distributions payable to non-controlling interests$75.8M$108.8M$98.2M$77.2M$72.8M$87.4M
Other accrued liabilities$68.6M$18.6M$3.1M$3.1M$53.2M$17.5M
Current portion of long-term debt$997.8M$998.6M$999.4M$380M$380M$380M
Lease Liability Payments - 2020 (Remaining Three Months)——$2M$1M—$3M
Operating Lease Liability Payments - 2024 (Lessee)——$3.8M$3.8M—$3.7M
Operating Lease Liability Payments - 2025 (Lessee)——$3.7M$3.7M—$3.8M
Lease Liability Payments - Due Year Two——$3.8M$3.8M—$3.7M
Lease Liability Payments - Due Year Three——$3.7M$3.7M—$3.7M
Lease Liability Payments - Due Year Four——$3.7M$3.7M—$3.8M
Lease Liability Payments - Remainder of Fiscal Year——$4.1M$4.1M—$3.8M
Note payable to DIRECTV$68.6M$18.6M$3.1M$3.1M$53.2M$17.5M
Operating lease liabilities, current——$20.8M$20M$19.3M$18.5M
Operating Lease Liability Payments Due——$24.2M$23.2M—$21.2M
Operating Lease Liability - Undiscounted Excess Amount——$3.4M$3.2M—$2.7M
Total current liabilities$1.3B$1.2B$1.2B$530.8M$636.2M$535.7M

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts receivable, net$783.8M$19.4B$19.4B$20.1B$20.5B$20B
Allowance for Credit Losses - Receivable (Current)$3.8B$3.7B$3.5B$3.5B$3.4B$2.7B
Cash and cash equivalents$929M$1.1B$631.9M$938.9M$618.7M$586.4M
Available For Sale Securities Debt Securities Current$58.2M$12.1M$13.2M$16.1M$18.8M$21.9M
Other current assets$4.2M$3.1M$4.5M$5.5M$6.9M$10.2M
Other royalty income receivable$27M$23.8M$27.7M$28.9M$29.3M$27.5M
Equipment Installment Plan Receivables, Gross$19.7B$19.4B$19.4B$20.1B$20.5B$20B
Finance Receivables (Current)$783.8M$716.6M$842.9M$860.1M$854.4M$779.8M
Financing Receivables$15.9B$15.7B$16B$16.6B$17.1B$17.3B
Loans and Lending Commitments$15.9B$15.7B$16B$16.6B$17.1B$17.3B
Prepaid expenses and other current assets$4.2M$3.1M$4.5M$5.5M$6.9M$10.2M
Short-term investments$58.2M$12.1M$13.2M$16.1M$18.8M$21.9M
Total current assets$1.8B$1.8B$1.5B$1.8B$1.5B$1.4B

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Additional paid-in capital$4.1B$4.2B$4.1B$4.1B$4.1B$4.4B
Deferred shares, $0.000001 par value; issued and outstanding: 2026–427,355 and 2025–411,475$0$0$0$0$0$0
Noncontrolling interests$3.4B$3.1B$3.2B$3.2B$3.2B$3B
Retained earnings$2.8B$2.5B$2.2B$2.3B$2.4B$2.5B
Share Price——$33.12———
Share Repurchase Authorization Limit—$2.3B$2B$1.9B—$1.7B
Share Repurchase Program - Amount Remaining—$2.3B$2B$1.9B—$1.7B
Total liabilities and stockholders' equity$18.2B$17.6B$18.3B$19.3B$19.6B$19.8B
Total stockholders' equity$10.3B$9.8B$9.5B$9.6B$9.7B$9.9B
Treasury stock$2.7M$2.7M$2.6M$2.6M$2.6M$2.7M

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Gross loans$15.9B$15.7B$16B$16.6B$17.1B$17.3B
Purchased Credit Deteriorated Loans$15.9B$15.7B$16B$16.6B$17.1B$17.3B
Deferred Tax Assets and Other Non-Current Assets$33.5M$36.7M$85.5M$86.6M$79.3M$76.9M
Equipment Installment Plan Receivables (Non-Current), Net$15.1B$15B$15.1B$15.8B$16.2B$16.5B
Equity method investments$379.4M$336.2M$275.9M$291M$290M$265.7M
Equity Securities (FV-NI) - Non-Current$187M$141.1M$110.5M$129.4M$171.3M$173.3M
Equity Securities (Non-Current)$187M$141.1M$110.5M$129.4M$171.3M$173.3M
Available-for-sale securities$693.5M$219M$271.9M$302.5M$419M$406.8M
Total investments$187M$141.1M$110.5M$129.4M$171.3M$173.3M
Goodwill$0—$924.6M$924.6M$924.6M$924.6M
Long-term marketable securities$693.5M$219M$271.9M$302.5M$419M$406.8M
Long-term financing receivables (net of allowances of $27 in 2026 and $34 in 2025)$15.1B$15B$15.1B$15.8B$16.2B$16.5B
Other non-current assets$33.5M$36.7M$85.5M$86.6M$79.3M$76.9M
Other non-current assets$15.1B$15B$15.1B$15.8B$16.2B$16.5B
Software and Technology Licenses, Net$33.5M$36.7M$85.5M$86.6M$79.3M$76.9M
Total assets$18.2B$17.6B$18.3B$19.3B$19.6B$19.8B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Nonperforming Loans and Leases Percentage$19.7B$19.4B$19.4B$20.1B$20.5B$20B
Accrued liabilities$0—$467.1M$502.9M$577.9M$648.7M
Quarterly conversion basis (in shares)—100.0%100.0%100.0%—100.0%
Number of votes per share—1.001.001.00—1.00
Less: net unamortized discount$187.6M$182.5M$177.5M$234.3M$229.1M$223.6M
Deferred stock, par value (in dollars per share)$0.00$0.00$0.00$0.00$0.00$0.00
Deferred stock, issued (in shares)392.3M394.5M409M409.9M411.5M427.4M
Deferred stock, outstanding (in shares)392.3M394.5M409M409.9M411.5M427.4M
Equity method investments (Note 11)$379.4M$336.2M$275.9M$291M$290M$265.7M
Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows$3.6B$3.4B$3.2B$3.2B$3.2B$2.5B
Financing Receivable, Allowance For Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)$238.1M$224.6M$216.7M$220.7M$212M$204.9M
Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows$16.1B$16B$16.2B$16.8B$17.3B$17.5B
Lessee Operating Lease Liability Payments Due——$24.2M$23.2M—$21.2M
Thereafter——$6.9M$6.9M—$3.1M
Lessee Operating Lease Liability Undiscounted Excess Amount——$3.4M$3.2M—$2.7M
Noncontrolling interests in subsidiaries$3.4B$3.1B$3.2B$3.2B$3.2B$3B
Number of classes of stock—2.002.002.00—2.00
Number of noncontrolling interests created—3.004.004.00—4.00
Total Commitments—————$825M
Unfunded Commitments—————$600M
Share price (in dollars per share)——$33.1———
Share Repurchase Program, Authorized, Amount—$3B————
Share Repurchase Program, Remaining Authorized, Amount—$2.3B$2B$1.9B—$1.7B
Remainder of Fiscal Year 2024——$2M$1M—$3M

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Debt - Unamortized Discount (Premium) and Issuance Costs, Net$187.6M$182.5M$177.5M$234.3M$229.1M$223.6M
Operating Lease Liability Payments - 2026 (Lessee)——$3.7M$3.7M—$3.7M
Operating Lease Liability Payments - 2027 (Lessee)——$3.7M$3.7M—$3.7M
Operating Lease Liability Payments - 2028 (Lessee)——$3.7M$3.7M—$3.8M
Long-term debt$6.6B$6.6B$7B$8.6B$8.6B$8.6B
Operating Lease Liabilities (Total)——$20.8M$20M$19.3M$18.5M
Other non-current liabilities$12.1M$17.9M$143.3M$126.9M$120.8M$117.8M
Total liabilities$7.9B$7.8B$8.8B$9.7B$9.9B$9.9B